Zacks: Brokerages Expect Kodiak Sciences Inc. (NYSE:KOD) Will Announce Earnings of -$0.46 Per Share

Brokerages expect Kodiak Sciences Inc. (NYSE:KOD) to announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kodiak Sciences’ earnings. Kodiak Sciences posted earnings of ($0.25) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 84%. The firm is expected to report its next quarterly earnings report on Thursday, March 26th.

On average, analysts expect that Kodiak Sciences will report full year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.25) to ($1.20). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.16) per share, with EPS estimates ranging from ($2.27) to ($2.04). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Kodiak Sciences.

Kodiak Sciences (NYSE:KOD) last released its earnings results on Tuesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33).

Several equities research analysts have commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $40.00 price target on shares of Kodiak Sciences in a report on Wednesday, November 13th. Zacks Investment Research lowered shares of Kodiak Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th.

NYSE:KOD traded down $3.30 during mid-day trading on Friday, hitting $25.63. The company’s stock had a trading volume of 687,528 shares, compared to its average volume of 174,722. Kodiak Sciences has a 1 year low of $5.65 and a 1 year high of $32.42. The business’s fifty day moving average is $21.01 and its two-hundred day moving average is $14.15.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in shares of Kodiak Sciences by 3.8% during the 3rd quarter. Rhumbline Advisers now owns 23,543 shares of the company’s stock worth $339,000 after purchasing an additional 866 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Kodiak Sciences by 179.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,476 shares of the company’s stock valued at $73,000 after acquiring an additional 4,161 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in Kodiak Sciences by 8.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 84,524 shares of the company’s stock valued at $989,000 after acquiring an additional 6,917 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Kodiak Sciences in the 2nd quarter valued at about $99,000. Finally, Morgan Stanley raised its holdings in Kodiak Sciences by 88.6% in the 2nd quarter. Morgan Stanley now owns 21,027 shares of the company’s stock valued at $246,000 after acquiring an additional 9,878 shares during the last quarter.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

See Also: When is a capital gain realized?

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.